Positive News Sentiment NYSE:AVNS Avanos Medical - AVNS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avanos Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $31.59 -0.16 (-0.50%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$31.23▼$31.8950-Day Range$25.97▼$31.7552-Week Range$19.32▼$35.91Volume284,781 shsAverage Volume199,071 shsMarket Capitalization$1.47 billionP/E Ratio35.10Dividend YieldN/APrice Target$29.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avanos Medical MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside7.1% Downside$29.33 Price TargetShort InterestBearish1.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.70Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth7.89%From $1.52 to $1.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.71 out of 5 starsMedical Sector829th out of 1,025 stocksSurgical Appliances & Supplies Industry18th out of 23 stocks 1.0 Analyst's Opinion Consensus RatingAvanos Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.33, Avanos Medical has a forecasted downside of 7.1% from its current price of $31.59.Amount of Analyst CoverageAvanos Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.95% of the float of Avanos Medical has been sold short.Short Interest Ratio / Days to CoverAvanos Medical has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Avanos Medical has recently increased by 3.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAvanos Medical does not currently pay a dividend.Dividend GrowthAvanos Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVNS. Previous Next 3.7 News and Social Media Coverage News SentimentAvanos Medical has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Avanos Medical this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Avanos Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avanos Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.08% of the stock of Avanos Medical is held by insiders.Percentage Held by Institutions92.08% of the stock of Avanos Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Avanos Medical are expected to grow by 7.89% in the coming year, from $1.52 to $1.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avanos Medical is 35.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Avanos Medical is 35.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.73.Price to Book Value per Share RatioAvanos Medical has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avanos Medical (NYSE:AVNS) StockAvanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm's portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.Read More Receive AVNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address AVNS Stock News HeadlinesJanuary 23, 2023 | finance.yahoo.comWhat Does Avanos Medical, Inc.'s (NYSE:AVNS) Share Price Indicate?January 18, 2023 | seekingalpha.comAVNS Avanos Medical, Inc.February 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 11, 2023 | finance.yahoo.comAvanos Medical, Inc. Announces New Leadership AppointmentsJanuary 9, 2023 | stocknews.com1 Health Care Stock Hedge Funds Are Buying Right NowJanuary 4, 2023 | finance.yahoo.comAvanos Medical, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 27, 2022 | finance.yahoo.comIs Avanos Medical, Inc.'s (NYSE:AVNS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?December 9, 2022 | finance.yahoo.com3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023February 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 3, 2022 | finance.yahoo.comAvanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?December 2, 2022 | finance.yahoo.comWhy Avanos Medical (AVNS) is a Top Momentum Stock for the Long-TermNovember 30, 2022 | finance.yahoo.comAvanos Medical, Inc. (NYSE:AVNS) Shares Could Be 45% Below Their Intrinsic Value EstimateNovember 14, 2022 | finance.yahoo.comAvanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & ProcurementNovember 3, 2022 | finance.yahoo.comStrong week for Avanos Medical (NYSE:AVNS) shareholders doesn't alleviate pain of five-year lossNovember 3, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Avanos Medical (AVNS)November 2, 2022 | seekingalpha.comAvanos Medical reports Q3 mixed earnings; reaffirms FY22 guidanceNovember 2, 2022 | finance.yahoo.comAvanos Medical, Inc. Announces Third Quarter 2022 ResultsNovember 2, 2022 | finance.yahoo.comAvanos Medical (AVNS) Tops Q3 Earnings EstimatesOctober 26, 2022 | nasdaq.comShareholders in Avanos Medical (NYSE:AVNS) are in the red if they invested three years agoOctober 26, 2022 | finance.yahoo.comAvanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2022 Financial ResultsOctober 11, 2022 | benzinga.comExpert Ratings for Avanos MedicalSeptember 12, 2022 | finance.yahoo.comStrength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?September 12, 2022 | seekingalpha.comAvanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting DebateSeptember 8, 2022 | finance.yahoo.comAvanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?September 2, 2022 | nasdaq.comAvanos Medical Enters Oversold Territory (AVNS)September 2, 2022 | nasdaq.comAvanos Medical Inc Shares Close in on 52-Week Low - Market MoverAugust 12, 2022 | seekingalpha.comAvanos Medical, Inc. (AVNS) CEO Joe Woody on Q2 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address AVNS Company Calendar Last Earnings11/02/2021Today2/05/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNYSE:AVNS CUSIPN/A CIK1606498 Webavanos.com Phone(844) 428-2667FaxN/AEmployees4,555Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.33 High Stock Price Forecast$34.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside-7.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.90 Trailing P/E Ratio35.10 Forward P/E Ratio20.78 P/E GrowthN/ANet Income$5.20 million Net Margins5.39% Pretax Margin8.15% Return on Equity5.74% Return on Assets4.20% Debt Debt-to-Equity Ratio0.20 Current Ratio2.90 Quick Ratio1.70 Sales & Book Value Annual Sales$795.90 million Price / Sales1.85 Cash Flow$1.95 per share Price / Cash Flow16.18 Book Value$26.23 per share Price / Book1.20Miscellaneous Outstanding Shares46,498,000Free Float45,531,000Market Cap$1.47 billion OptionableOptionable Beta0.90 Key ExecutivesJoseph F. WoodyChief Executive Officer & Executive DirectorMichael C. GreinerSVP, Chief Financial & Transformation OfficerLee BurnesSenior VP-Global Research & DevelopmentMichelle ScharfenbergSenior VP, Chief Ethics & Compliance OfficerWilliam D. HaydonSenior VP & General Manager-Pain FranchiseKey CompetitorsEstablishment LabsNASDAQ:ESTAInogenNASDAQ:INGNVicarious SurgicalNYSE:RBOTEnovisNYSE:ENOVArcellxNASDAQ:ACLXView All CompetitorsInsiders & InstitutionsJanney Montgomery Scott LLCBought 11,188 shares on 2/1/2023Ownership: 0.024%Zurcher Kantonalbank Zurich Cantonalbank Bought 1,353 shares on 2/1/2023Ownership: 0.017%New York State Common Retirement FundBought 1,353 shares on 1/30/2023Ownership: 0.121%Versor Investments LPSold 11,145 shares on 1/30/2023Ownership: 0.031%New York State Teachers Retirement SystemBought 4,700 shares on 1/27/2023Ownership: 0.189%View All Institutional Transactions AVNS Stock - Frequently Asked Questions Should I buy or sell Avanos Medical stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares. View AVNS analyst ratings or view top-rated stocks. What is Avanos Medical's stock price forecast for 2023? 2 brokerages have issued 12-month target prices for Avanos Medical's shares. Their AVNS share price forecasts range from $26.00 to $34.00. On average, they expect the company's stock price to reach $29.33 in the next year. This suggests that the stock has a possible downside of 7.1%. View analysts price targets for AVNS or view top-rated stocks among Wall Street analysts. How have AVNS shares performed in 2023? Avanos Medical's stock was trading at $27.06 at the beginning of the year. Since then, AVNS stock has increased by 16.7% and is now trading at $31.59. View the best growth stocks for 2023 here. Are investors shorting Avanos Medical? Avanos Medical saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 863,600 shares, an increase of 19.2% from the December 15th total of 724,600 shares. Based on an average trading volume of 224,100 shares, the days-to-cover ratio is currently 3.9 days. Approximately 1.9% of the shares of the company are sold short. View Avanos Medical's Short Interest. When is Avanos Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our AVNS earnings forecast. How were Avanos Medical's earnings last quarter? Avanos Medical, Inc. (NYSE:AVNS) issued its quarterly earnings data on Tuesday, November, 2nd. The company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.27 by $0.02. The business had revenue of $184.10 million for the quarter, compared to the consensus estimate of $183.90 million. Avanos Medical had a trailing twelve-month return on equity of 5.74% and a net margin of 5.39%. During the same period in the prior year, the business posted $0.21 earnings per share. What guidance has Avanos Medical issued on next quarter's earnings? Avanos Medical issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of $1.45-$1.65 for the period, compared to the consensus EPS estimate of $1.51. The company issued revenue guidance of $815.00 million-$835.00 million, compared to the consensus revenue estimate of $824.62 million. What is Joseph F. Woody's approval rating as Avanos Medical's CEO? 32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Avanos Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA). What is Avanos Medical's stock symbol? Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS." Who are Avanos Medical's major shareholders? Avanos Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (1.19%), New York State Teachers Retirement System (0.19%), New York State Common Retirement Fund (0.12%), Allspring Global Investments Holdings LLC (0.12%), Exchange Traded Concepts LLC (0.08%) and Ziegler Capital Management LLC (0.07%). Insiders that own company stock include Gary Blackford and Patrick J Oleary. View institutional ownership trends. How do I buy shares of Avanos Medical? Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avanos Medical's stock price today? One share of AVNS stock can currently be purchased for approximately $31.59. How much money does Avanos Medical make? Avanos Medical (NYSE:AVNS) has a market capitalization of $1.47 billion and generates $744.60 million in revenue each year. The company earns $5.20 million in net income (profit) each year or $0.90 on an earnings per share basis. How many employees does Avanos Medical have? The company employs 4,555 workers across the globe. How can I contact Avanos Medical? Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com. This page (NYSE:AVNS) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.